Earnings ·
Vaxart, Inc. reported second quarter 2026 financial results on August 6, 2026
VXRTVaxart, Inc.
Vaxart, Inc. reported second quarter 2026 financial results on August 6, 2026. The company generated $27.2 million in revenue, down from $39.7 million in the prior year period, primarily due to lower government contract activity. Research and development expenses decreased to $33.7 million from $49.7 million, while general and administrative expenses rose to $6.6 million from $4.6 million. The company reported a net loss of $13.5 million, or $0.06 per share, compared to a $15.0 million loss in the previous year. Cash, cash equivalents, and investments totaled $64.0 million as of June 30, 2026, providing a runway into the second quarter of 2027. Clinically, Vaxart announced topline safety data from its Phase 2b COVID-19 sentinel cohort of 400 participants, showing no vaccine-related serious adverse events. Topline efficacy and safety data for the full study of approximately 5,000 participants are expected in the first half of 2027. The company operates in the biotechnology industry, developing oral recombinant pill vaccines.